Investment Q&A

Q: Do you have any updated information on this stock and what are your views on it.

Q: The market seems to like the news but I would appreciate your views on their just released Q1 results. I realize that they still came in at a loss but that was solely attributable to an increase in operating costs (specifically R&D and a ramp up of its US sales force in advance of the release of SavvyWire). I remain surprised that we're still trading below their recent financing level. Thanks as always.

Q: I am currently down about 60% on WELL Health
- I am considering buying more to average down on my cost

Your thoughts?

Thanks,
M

Q: Your analysis of AXSM.US would be appreciated. Any news on the reasons for the large drop.

Thanks

Thomas

Q: Why the big drop in price today?

Q: We often see conflicting analyst opinions, but ratings of MDT seem to be on one extreme or other. For what it’s worth, MDT appears on various lists of “best stocks for 2023”. And just this week, Barrons carried this story: “ Buy Medtronic Stock. Shares of the Dividend Aristocrat Look Attractive” (January 2). This morning RBC-DI downgraded MDT from outperform while CFRA maintains a Buy. Both RBC-DI and CFRA seem to reasonably good track records. I have held MDT shares from multi-year highs all the way down to today’s miserable level. (Tax loss not useable).

I have previously asked you about MDT and possibly others here may have done so too. Would you care to take a side in this frustrating debate with your reasons? Thanks.

Q: Could you provide any information/prospects on the above stock? Thanks.

Q: Asked by Doris on January 09, 2023
5I RESEARCH ANSWER:
We are not big fans of the staples sector overall right now in the US. It has fared decently over the last year but valuations are at the higher end now, as growth should moderate alongside inflation. Also, now that bonds offer more attractive yields, we think the relative attractiveness of staples is lower than it was a year ago (more safe alternatives for stability and yield now).

We think it is difficult to be too hard on COST though. Overall, we think staples names in Canada look a bit more attractive due to what looks like lower valuations on average. In Canada, we think PBH, ATD and NWC are worth looking at.

this is an answer you gave regarding staples . would you feel the same eay about hwalthcare stocks, such as gilead, etc

Q: what is your feeling on Medtronic now? If I buy it in a US RRSP is there still a whitholding tax?

Q: I'm wondering about the big drop in JNJ today?

Q: I'm wanting to increase my holdings in US healthcare. For share price appreciation and safety, which would you prefer and why?

Q: Hello 5i, could you comment on PRN as the stock price is going up quit a bit.

Q: I have no Healthcare companies in my portfolio. What names are you presently recommending; Canadian and/or US $. Thanks.

Q: The top 10 holdings (50% +) have a dividend yield of 0 to 4 % yield. The ETF shows a yield of 8.46%. Could you explain the discrepancy ? I like the sector. Beside HHL could recommend a other ETF.

Q: Does the recent acquisition have a significant impact on QIPTs prospects?

Q: This US REIT has been beaten and sits near its 2022 low with a healthy divvy. It holds quality medical offices located near hospitals which should provide it with some pricing power with doctors wanting to locate close to where they perform surgeries. Is the dividend safe? How would you categorize their debt? Is this one you'd recommend or avoid? Any other concerns? Lastly how does this compare with MPW? Appreciate your views.

Q: hi folks:

below is your reply/update from july 12,2022 on these 4 pot stocks

seems like the only catalyst will be the pending legislative change in the usa

i am curious for your update on these names, with a comment on potential survivability (or, i guess, lack of same)


thanks again

merry christmas to you and your families


unless that offends you, then happy holidays...............


july2022
GRWG is the smallest of the names, with a market cap of $256.3M, whereas GTII has a market cap of $2.8B, TRUL $3.0B, and CURA $4.6B. Revenue growth is strong among all four companies. GRWG has had the most volatility in price and its balance sheet is quite strong, but it does issue shares to fund its operations. GTII has good profit margins and is at a reasonable valuation (2.0X sales, 30.1X P/E, and 1.3X book value). TRUL has shown volatility in its profitability and its valuation is OK (1.7X sales, 37.3X P/E, and 1.0X book). CURA is not profitable and has a high valuation.

We think that GTII has demonstrated its resiliency and is the strongest of the four names. Although GRWG is the smallest, we like its profitability and strong balance sheet. We would then rank TRUL and CURA following GTII and GRWG. Although, the momentum in shares for all four names is not the greatest and we would prefer to wait until investor appetite for growth stocks has returned before becoming interested in these names.

Q: What are your thoughts on Sienna Senior Living Inc. as an investment? Do you see this as a good opportunity at the present time and with good long-term prospects? Seems to have a good dividend yield etc. and wondering if you have any thoughts?

Q: Can you tell us how much cash per share Fulgent still has, after the acquisition of Fulgent Pharma? This move was obviously not liked by the market. Does its current stock price make it an attractive investment in the medium to long term? Hold, buy or sell?

Q: I checked out the 5i Profile page for Theratechnologies to see if there was any news regarding the large drop on December 1st but didn't see anything. I checked out Theratechnologies Investor Relations website and found the press release regarding the enrollment pause on the Phase 1 clinicial trial of TH1902. Why doesn't this press release show up in the News & Media section on TH's Profile in 5i?